Novamind has bold plans for building out a psychedelic ecosystem. One that spans from ketamine-assisted psychotherapy and psilocybin retreats to novel clinical trials. In April 2022, Novamind was acquired by Numinus.
Novamind
“Novamind is building a global network of clinics and retreats that are required for a regulated psychedelics industry. We provide access to safe, legal psychedelic experiences, while advancing research for psychedelic medicine.”
Novamind has sponsored TheraPsil, a non-profit that promotes the (medical) use of psilocybin in Canada. The press release (below) however isn’t clear about specific monetary sponsorship.
They have also bought a ketamine-assisted psychotherapy clinic (formally) called Cedar Psychiatry and have invested (and since divested at a 60% profit) in Synthesis.
Novamind is listed on the CNSX under the ticker NM.
Key Staff
- Jesse Kaplan – Director
- Yaron Conforti – CEO & Director
- Sruli Weinreb – Director
- Nolan Ladouceur – VP & Business Development
- Reid Robison – CMO
News
- Novamind Closes Oversubscribed CAD$10 Million Private Placement (November 2020)
- Novamind Sponsors TheraPsil, an Advocate for the Compassionate Use of Psilocybin in Canada (July 2020)
- Novamind Closes the Acquisition of Cedar Psychiatry, a Leading Psychedelic Therapy Organization in the U.S. (July 2020)
- Novamind Announces Closing of Oversubscribed Private Placement (July 2020)
Activities
B2B
B2C
Clinic
Topics of Interest
Depression
Eating Disorders
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research (Novamind, 12 April 2022)Group Ketamine Pilot; Therapist Training Platform's Seed Round; Durable Response to PAT at 12 Month Follow up (The Trip Report, 18 February 2022)
The Trip Report goes through the latest psychedelic news from February 2022. Highlights include Novamind's ketamine-assisted therapy, Fluence's $3 million seed round, and reporting on the 12-month Johns Hopkins depression follow-up study.
Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety (Novamind, 16 March 2022)
Novamind Partner to Acquire Specialized Ibogaine Group in Brazil (Novamind, 31 March 2022)
Novamind Partners with Uruguay-Based Bienstar Wellness to Develop Latin America's First Integrative Mental Health Clinic Network (, 01 December 2021)